Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

treated with interferon and ribavirin alone, although conclusions regarding safety cannot be made until results in more patients over longer duration are known.  Positive preliminary SVR data were also presented.
  • AASLD 2010, IL28B Poster data showed that the addition of ANA598 to SOC has the potential to confer beneficial effect on HCV patients regardless of IL-28B genotype.
  • EASL 2010 and ICAR 2010, Preclinical Posters – presented data showing enhanced antiviral activity and suppression of resistance when ANA598 is combined in vitro with other anti-HCV agents that act through diverse mechanisms, including protease inhibition, polymerase inhibition (both nucleoside and non-nucleoside inhibitors) and cyclophilin inhibition (a host target).

  • Conference Call WebcastAnadys will host a conference call at 5:00 pm Eastern Standard Time today to discuss its fourth quarter and year-end 2010 financial results and highlights.  A live webcast of the call, including accompanying slides, will be available online at www.anadyspharma.com.  A telephone replay will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 62030425.  The webcast and telephone replay will be available through March 17, 2011.Condensed Consolidated Financial StatementsAnadys Pharmaceuticals, Inc.Condensed Consolidated Statements of Operations(In thousands except per share amounts)(Unaudited)Three Months EndedDecember 31,Twelve Months EndedDecember 31,2010200920102009Operating expensesResearch and development

    $

    2,753$

    3,948$

    12,026$

    19,494General and administrative1,7271,6326,4788,243Total operating expenses (1)4,4805,58018,50427,737Interest income and other, net2544139610Gain (loss) from valuation of common sto
    '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
    4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
    5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
    6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/16/2015)... Bythewood, South Carolina (PRWEB) April 17, 2015 ... solutions and steam system services, released their newly ... 2015. The customer facing website effectively promotes ... proposition. , All the information that a ... training, steam system services, company capabilities, industries serviced, ...
    (Date:4/16/2015)... Francisco, CA (PRWEB) April 16, 2015 ... scheduled to report first quarter results on Thursday, April ... announcement, Cytokinetics’ senior management will host a conference call ... financial results and the company’s outlook for the future. ... can be accessed from the homepage and in the ...
    (Date:4/16/2015)...  Schulman Associates IRB, Inc., the industry-leading central IRB ... lease on Laboratory Drive in the heart of ... location will house review board and service staff, which ... and customer service to clients. CBRE ... the deal, while Capital Associates Management, LLC represented the ...
    (Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
    Breaking Biology Technology:Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2OncoTAb Names Dr. David L. Cooper as COO 2
    ... April 30 Interleukin,Genetics, Inc. (Amex: ILI ... M.,Lurier, CPA, as its Chief Financial Officer., ... Genetics, Inc.,commented on the appointment, "Eliot is an ... spirit and a proven,record of achievement in managing ...
    ... AEterna Zentaris Inc.,(NASDAQ: AEZS , TSX: AEZ), ... oncology, today announced that Prof. Frans M.J.,Debruyne, M.D., ... Institutes,in The Netherlands, won the award for Best ... Annual European Association of Urology Meeting, which,was held ...
    ... Viral Load Assay, ORANGE COUNTY, Calif., April ... ) announced today that it has licensed certain,rights ... from Siemens Healthcare,Diagnostics. Under the agreement, Beckman Coulter ... HCV blood test for use on the company,s,molecular ...
    Cached Biology Technology:Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer 2Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 2AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 4AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 5AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 6Beckman Coulter Acquires Rights to Hepatitis C Virus 2
    (Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
    (Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
    (Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
    Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
    ... physical world. That,s a fact cancer researchers are beginning to ... mathematics in their efforts to understand how cancer develops -- ... researchers at the University of Michigan Comprehensive Cancer Center, has ... of the top cancer research journals and a new grant ...
    ... once discussed only in scientific or eco-centric circles, has ... sustainability remains elusive. On Friday, scholars and legal ... address how to meet mankind,s present needs without compromising ... The Environmental & Energy Law & Policy Journal,s fifth ...
    ... chemicals from plant material could produce liquid fuel for just ... the infrastructure is set up in the right way, states ... Bioproducts & Biorefining . Developed by scientists at the ... as bioliq, and is able to produce a range of ...
    Cached Biology News:Physics, math provide clues to unraveling cancer 2Symposium at UH will address how to put 'sustainability' into practice 2Novel technology could produce biofuel for around 0.50 a liter ($2.49 a gallon) 2
    RNA oligomers from 10 to 50 bases purified by PAGE and MS-checked. RNAs are supplied dried and fully deprotected....
    ... The iEMS Incubator/Shaker HT ... Thus, the iEMS Incubator/Shaker HT ... as DNA hybridization and primer ... HT is available as a ...
    ... a modified cap analog in which the ... replaced with OCH3. Because of this substitution, ... with the remaining hydroxyl group thus forcing ... a result, unlike transcripts synthesized with conventional ...
    ...
    Biology Products: